Recombinant Human Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1)

What is KIR2DL1 and what is its role in immune regulation?

KIR2DL1 (also known as CD158a, formerly NKAT1) is a 348 amino acid type I transmembrane glycoprotein belonging to the human killer cell immunoglobulin-like receptor (KIR) family. It is primarily expressed on human CD56dim NK cells and certain T cell subsets, where it functions as an inhibitory receptor regulating effector functions in the innate immune system . KIR2DL1 contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within its long cytoplasmic tail that mediate inhibitory signaling by blocking activating receptor clustering when engaged with its ligand . Through this mechanism, KIR2DL1 plays a crucial role in NK cell self-tolerance and prevents autoimmunity while maintaining surveillance against abnormal cells.

How does KIR2DL1 differ from other KIR family members in structure and ligand specificity?

KIR2DL1 is distinguished from other KIR family members by its specific extracellular domain structure and ligand binding preferences. While it shares high amino acid sequence identity (92%) with KIR2DL2 in the extracellular domain, their ligand specificities differ significantly . KIR2DL1 specifically targets HLA-C2 allotypes containing lysine at position 80 (Lys80), whereas KIR2DL2 recognizes HLA-C1 allotypes containing asparagine at position 80 (Asn80) . This ligand specificity is crucial for understanding NK cell function, as together KIR2DL1-3 recognize and inhibit NK cytotoxicity against cells expressing any HLA-C allotype, allowing self-recognition while potentially conferring susceptibility to certain diseases like leukemia .

What methods are recommended for detecting KIR2DL1 expression on NK cells?

For accurate detection and quantification of KIR2DL1 expression on NK cells, flow cytometry represents the gold standard approach. This method allows researchers to simultaneously quantify both the abundance of KIR2DL1 on the cell surface (measured by median fluorescence intensity, MFI) and the percentage of NK cells expressing KIR2DL1 .

Recommended protocol:

• Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation

• Stain cells with fluorochrome-conjugated antibodies specific for:

  • CD3 (to exclude T cells)

  • CD56 (to identify NK cells)

  • KIR2DL1-specific antibody (ensure specificity, as cross-reactivity with other KIRs can occur)

• Include appropriate isotype controls and single-color controls for compensation

• Analyze samples using multiparameter flow cytometry

• Gate on CD3-CD56+ NK cells and assess KIR2DL1 expression

When interpreting results, consider that KIR2DL1 expression can be influenced by genetic factors such as copy number variation and allelic polymorphisms, which should be accounted for in experimental design and analysis .

How do polymorphisms in KIR2DL1 affect its expression and function?

KIR2DL1 exhibits significant allelic polymorphism that substantially impacts both its expression level and functional capacity. Research has identified several key single nucleotide polymorphisms (SNPs) that alter receptor behavior:

• rs2304224 T variant: This polymorphism is associated with a 1.54-fold increase in KIR2DL1 surface expression and a 1.41-fold increase in the percentage of KIR2DL1+ NK cells (p=0.0002 and p=0.03, respectively) . Interestingly, this variant is also associated with decreased expression of its ligand HLA-C in individuals carrying HLA-C2 (p=0.0059), suggesting a compensatory mechanism in receptor-ligand evolution .

• Arginine at position 245 (R245): The presence of this residue in the transmembrane domain significantly enhances inhibitory function. Compared to R245-negative alleles, KIR2DL1 alleles containing R245 demonstrate:

  • Enhanced recruitment of Src-homology-2 domain-containing protein tyrosine phosphatase 2 and β-arrestin 2

  • Greater inhibition of lipid raft polarization at the immune synapse

  • Increased stability of surface expression when interacting with ligands

These polymorphisms contribute to functional heterogeneity among KIR2DL1 alleles, affecting their ability to inhibit NK cell degranulation, interferon-γ production, and cytotoxicity against target cells expressing the HLA-Cw6 ligand .

What is the relationship between KIR2DL1 copy number variation and cell surface expression?

The relationship between KIR2DL1 copy number variation and its surface expression presents an interesting pattern. While copy number significantly affects the proportion of NK cells expressing KIR2DL1, it has a less pronounced effect on the expression level per cell:

• KIR2DL1+ NK cell percentage: Individuals carrying two copies of KIR2DL1 (homozygous or heterozygous) show a 2.16-fold higher percentage of KIR2DL1+ NK cells compared to individuals with only one copy (p=0.0001) .

• Surface expression intensity: The abundance of KIR2DL1 on NK cell surfaces (measured by MFI) shows only a borderline, non-significant difference between individuals with one versus two copies of the gene (p=0.0594) .

This differential effect suggests distinct regulatory mechanisms governing the frequency of receptor-positive cells versus the density of receptor expression per cell. These findings align with previous research by Béziat et al., reinforcing the observation that copy number more strongly influences the proportion of cells expressing the receptor rather than expression levels on individual cells .

How does the presence of HLA-C2 ligands affect KIR2DL1 expression?

The presence of HLA-C2 ligands demonstrates a regulatory effect on KIR2DL1 expression levels in what appears to be a feedback mechanism. Research indicates that KIR2DL1 expression is significantly decreased in individuals homozygous for the C2 ligand (C2/C2, p=0.007) . This suggests an adaptation mechanism where receptor expression is modulated based on the availability of its cognate ligand.

• Le Luduec et al. observed that KIR2DL1 expression associates with C2 presence in a dose-dependent manner

• More recent research found this association only in individuals carrying two copies of C2, not in heterozygotes

This ligand-mediated regulation of receptor expression represents an important consideration for experimental design when studying KIR2DL1 function, as the HLA-C genotype of study subjects may significantly impact baseline receptor expression.

What assays are most effective for analyzing KIR2DL1 inhibitory function?

For comprehensive assessment of KIR2DL1 inhibitory function, multiple complementary assays should be employed to measure different aspects of NK cell response inhibition:

• Degranulation assay:

  • Measure CD107a surface expression on NK cells following stimulation with target cells expressing HLA-C2

  • Compare NK cells expressing different KIR2DL1 alleles or NK cells with KIR2DL1 knocked out/down

  • Include appropriate controls (HLA-C1 expressing targets or blocking antibodies)

• Cytokine production assay:

  • Measure interferon-γ production by intracellular cytokine staining or ELISA following co-culture with target cells

  • Compare inhibition levels between different KIR2DL1 variants

• Cytotoxicity assay:

  • Standard chromium release assay or flow cytometry-based killing assay using labeled target cells

  • YT-Indy cells (an NK cell line) transfected with different KIR2DL1 alleles can be particularly useful for standardized comparisons

• Biochemical analysis of inhibitory signaling:

  • Immunoprecipitation to assess recruitment of signaling molecules like SHP-2

  • Phosphorylation assays to measure inhibition of activating signaling pathways

  • Analysis of lipid raft polarization at the immune synapse, which is differentially affected by KIR2DL1 variants

When comparing different KIR2DL1 alleles or conditions, researchers should account for variables such as surface expression levels, HLA-C genotype, and the presence of other inhibitory or activating receptors that may influence results.

How can recombinant KIR2DL1 be effectively used in immunological research?

Recombinant KIR2DL1 proteins, such as the KIR2DL1/CD158a Fc chimera protein, offer versatile research tools for investigating receptor-ligand interactions and NK cell function. Effective applications include:

• Binding studies:

  • Use recombinant KIR2DL1-Fc fusion proteins to assess binding affinity to various HLA-C allotypes

  • Employ surface plasmon resonance (SPR) or ELISA-based methods to quantify binding kinetics

  • Compare binding of different KIR2DL1 allelic variants to identify structural determinants of ligand recognition

• Blocking studies:

  • Apply recombinant KIR2DL1 to compete with cell-surface KIR2DL1 for binding to HLA-C2, thereby blocking inhibitory signaling

  • Assess functional consequences on NK cell activation, cytotoxicity, and cytokine production

  • Use as a potential therapeutic approach to enhance NK cell activity against tumors

• Development of detection reagents:

  • Generate antibodies against recombinant KIR2DL1 for flow cytometry and immunohistochemistry

  • Create multimeric complexes to identify and quantify HLA-C2-expressing cells

• Structural analysis:

  • Utilize purified recombinant protein for crystallography studies to determine three-dimensional structure

  • Investigate the molecular basis of allelic variations in receptor function

When working with recombinant KIR2DL1, researchers should confirm protein quality through SDS-PAGE, verify functionality through binding assays, and consider the effects of any fusion tags or modifications on receptor behavior .

What methods can be used to study the molecular mechanisms of KIR2DL1 signaling?

To elucidate the molecular mechanisms underlying KIR2DL1 signaling, researchers can employ several sophisticated approaches:

• Signaling protein recruitment analysis:

  • Immunoprecipitation followed by western blotting to detect recruitment of signaling molecules like SHP-2 and β-arrestin 2 to KIR2DL1

  • Proximity ligation assays to visualize protein-protein interactions in intact cells

  • FRET or BRET assays to monitor real-time interactions between KIR2DL1 and signaling molecules

• Lipid raft and immune synapse analysis:

  • Confocal microscopy with fluorescently labeled antibodies or fusion proteins to visualize distribution of receptors and signaling molecules at the immune synapse

  • Lipid raft isolation through detergent-resistant membrane fractionation

  • Live-cell imaging to track dynamic changes in receptor clustering and signaling complex formation

• Mutagenesis studies:

  • Site-directed mutagenesis of key residues (such as R245) to assess their impact on signaling efficiency

  • Creation of chimeric receptors to identify domains critical for specific signaling functions

  • CRISPR/Cas9 genome editing to introduce specific KIR2DL1 variants into primary NK cells or cell lines

• Phosphorylation pathway analysis:

  • Phospho-specific antibodies to monitor changes in phosphorylation of signaling molecules downstream of KIR2DL1

  • Phosphoproteomics to comprehensively identify targets affected by KIR2DL1 signaling

  • Specific inhibitors of signaling components to dissect the pathway

These approaches have revealed that KIR2DL1 alleles containing R245 recruit more SHP-2 and β-arrestin 2, leading to enhanced inhibition of lipid raft polarization at the immune synapse and greater stability of surface expression compared to R245-negative alleles .

What is the evidence linking KIR2DL1 polymorphisms to autoimmune diseases?

Research has established significant associations between KIR2DL1 polymorphisms and autoimmune conditions, particularly Type 1 Diabetes Mellitus (T1DM). A comprehensive meta-analysis of 13 independent case-control studies comprising 2076 T1DM cases and 1967 controls revealed:

The protective association is biologically plausible given KIR2DL1's role in inhibiting NK cell activity, potentially reducing autoimmune-mediated destruction of pancreatic β-cells. This inhibitory function may help maintain self-tolerance, with certain KIR2DL1 variants providing more effective inhibition of NK cell-mediated cytotoxicity against self tissues.

Table 1: Meta-analysis findings for KIR2DL1 association with T1DM

*Specific values not statistically significant in ethnic subgroup analysis

How might KIR2DL1 functional variations impact transplantation outcomes?

The functional heterogeneity among KIR2DL1 alleles has significant implications for transplantation outcomes, particularly in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation. The presence of specific KIR2DL1 variants in donors or recipients may influence:

• Graft-versus-host disease (GvHD) risk: KIR2DL1 alleles with enhanced inhibitory function (such as those containing R245) may reduce the risk of GvHD by providing stronger inhibitory signals to donor NK cells, preventing inappropriate targeting of recipient tissues .

• Graft-versus-leukemia (GvL) effect: Conversely, strongly inhibitory KIR2DL1 variants might reduce beneficial GvL effects by limiting NK cell activity against residual leukemic cells.

• Engraftment success: The balance between donor NK cell inhibition and activation influences the success of engraftment, with KIR2DL1 variants potentially affecting this balance.

• Donor selection strategies: Understanding a donor's KIR2DL1 allelic profile could inform donor selection for optimal transplantation outcomes based on the recipient's HLA-C status.

Research indicates that KIR2DL1 alleles vary significantly in their ability to inhibit degranulation, interferon-γ production, and cytotoxicity, with molecular determinants like R245 affecting both signaling efficiency and receptor surface stability . These functional differences provide a mechanistic understanding of how KIR2DL1 allelic polymorphism may impact transplantation outcomes and could inform donor selection strategies.

What are the methodological approaches for studying KIR2DL1 in disease contexts?

Investigating KIR2DL1 in disease contexts requires a comprehensive methodological approach that integrates genetic, functional, and clinical analyses:

• Genetic association studies:

  • Case-control design comparing KIR2DL1 gene presence/absence between patients and healthy controls

  • Genotyping for specific allelic variants, particularly those affecting function (e.g., R245 status)

  • Analysis of gene copy number variation

  • Consideration of KIR-HLA combinations, since KIR2DL1 function depends on interaction with HLA-C2 ligands

• Functional assessment:

  • Ex vivo analysis of NK cells from patients and controls to assess KIR2DL1 expression and function

  • Comparison of inhibitory capacity between different patient groups

  • Correlation of functional data with genetic findings and clinical outcomes

• Longitudinal studies:

  • Monitoring KIR2DL1+ NK cell frequencies and function over disease course

  • Assessing impact of therapeutic interventions on KIR2DL1-mediated regulation

  • Correlation with disease activity markers

• Integrated analytical approaches:

  • Multivariate analysis incorporating KIR2DL1 genetics, expression, function, and clinical parameters

  • Stratification of patients based on KIR2DL1/HLA combinations to identify subgroups with distinct disease risk or progression patterns

These approaches have yielded important insights, including the protective association of KIR2DL1 against T1DM in meta-analysis studies (OR = 0.71) , and the identification of significant functional heterogeneity among KIR2DL1 alleles that may influence disease susceptibility and progression .

How do KIR2DL1 and HLA-C genes co-evolve, and what are the implications for NK cell function?

The co-evolution of KIR2DL1 and HLA-C genes represents a fascinating example of genetic adaptation in immune regulation. Evidence from comparative genomics and population genetics reveals several key aspects of this co-evolutionary relationship:

• Complementary expression regulation: Research has identified an apparent compensatory mechanism where the KIR2DL1 variant rs2304224 T is associated with both increased KIR2DL1 expression and decreased expression of its ligand HLA-C in individuals carrying HLA-C2 (p=0.0059) . This suggests selective pressure maintaining optimal receptor-ligand interactions.

• Signals of positive selection: Extended haplotype homozygosity analysis has identified signals of positive selection for rs4806553 G and rs687000 G variants, which are in linkage disequilibrium with rs2304224 T . This provides evidence for recent selective pressure on KIR2DL1 variants that affect receptor expression.

• Reciprocal regulation mechanisms: KIR2DL1 expression is decreased in individuals homozygous for the C2 ligand (C2/C2, p=0.007) , suggesting the existence of feedback mechanisms that tune receptor expression based on ligand availability.

These co-evolutionary dynamics likely reflect balancing selection pressures from infectious disease resistance (favoring diverse and potentially activating KIR-HLA combinations) versus autoimmunity risk (favoring inhibitory combinations that maintain self-tolerance). The resulting variation contributes to individual differences in NK cell education, licensing, and functional responsiveness, with implications for infection susceptibility, autoimmunity risk, reproductive success, and cancer immunosurveillance.

What are the challenges in designing experiments to study KIR2DL1 specificity and function?

Researchers face several significant challenges when designing experiments to study KIR2DL1 specificity and function:

• Genetic complexity:

  • High polymorphism of both KIR2DL1 and HLA-C genes

  • Linkage disequilibrium with other KIR genes

  • Copy number variation affecting expression levels

  • Need to account for these variables in experimental design and interpretation

• Receptor expression heterogeneity:

  • Variable expression of KIR2DL1 between individuals and between NK cell subsets

  • Influence of the HLA-C background on receptor expression levels

  • Challenges in normalizing for these differences when comparing functional outputs

• Antibody specificity issues:

  • Cross-reactivity between KIR2DL1 and other KIR family members

  • Difficulty in developing allele-specific antibodies that can distinguish functional variants

  • Need for careful validation of reagents for specificity

• Functional redundancy:

  • Overlapping and complementary functions with other inhibitory receptors

  • Difficulties in isolating KIR2DL1-specific effects from those of other receptors

  • Complex integration of signals from multiple receptors

• NK cell education effects:

  • NK cell responsiveness is calibrated by inhibitory receptor engagement during development

  • KIR2DL1+ NK cells from individuals with or without HLA-C2 may have different baseline responsiveness

  • Need to consider the educational status of NK cells when interpreting functional studies

To address these challenges, researchers should consider comprehensive genetic typing of experimental subjects, careful matching of cases and controls, inclusion of appropriate functional controls, and multi-parameter analysis approaches that can account for the complexity of NK cell regulation.

How might cutting-edge technologies advance our understanding of KIR2DL1 biology?

Emerging technologies offer exciting opportunities to deepen our understanding of KIR2DL1 biology across multiple domains:

• Single-cell analysis technologies:

  • Single-cell RNA sequencing to characterize KIR2DL1+ NK cell subsets and their functional states

  • Single-cell proteomics to profile the co-expression of multiple receptors and signaling molecules

  • Combined single-cell transcriptomics and epigenetics to understand receptor expression regulation

  • These approaches can reveal previously unrecognized NK cell subsets defined by KIR2DL1 expression and functional heterogeneity within KIR2DL1+ populations

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize nanoscale organization of KIR2DL1 at the immune synapse

  • Live-cell imaging with fluorescent reporters to track real-time dynamics of inhibitory signaling

  • Multiplexed imaging to simultaneously visualize multiple components of the signaling pathway

  • These methods can provide unprecedented insight into the spatial and temporal dynamics of KIR2DL1 function

• CRISPR/Cas9 genome editing:

  • Precise modification of KIR2DL1 variants in primary NK cells or cell lines

  • Creation of isogenic cell lines differing only in specific KIR2DL1 polymorphisms

  • Genome-wide CRISPR screens to identify novel regulators of KIR2DL1 expression and function

  • These approaches allow direct testing of the functional impact of specific genetic variants

• Structural biology advances:

  • Cryo-electron microscopy to determine high-resolution structures of KIR2DL1-HLA-C complexes

  • Molecular dynamics simulations to understand how polymorphisms affect receptor-ligand interactions

  • These methods can provide molecular insights into how specific residues influence binding and signaling

By integrating these technological approaches with traditional genetic and functional studies, researchers can develop a more comprehensive understanding of how KIR2DL1 variation impacts NK cell function in health and disease, potentially leading to novel immunotherapeutic strategies targeting this receptor pathway.